-

DiaMedica Therapeutics to Present at the 17th Annual Craig-Hallum Institutional Investor Conference on May 27, 2020

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 17th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, May 27, 2020. Management will be available to participate in one-on-one meetings. Meetings will take place virtually given the ongoing call for social distancing due to the Covid-19 pandemic. Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. The Company recently released positive top-line results from its phase II study in acute ischemic stroke and has a phase II study ongoing in chronic kidney disease. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”

For more information, please visit www.diamedica.com.

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

Industry:

DiaMedica Therapeutics Inc.

NASDAQ:DMAC
Release Versions
English

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

More News From DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the dosing of the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199 (rinvecalinase alfa) for the treatment of fetal growth restriction (FGR). This is the first clinical evaluation of DM199 in FGR. The open-label, single-arm study is design...

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding the need for additional nonclinical reproductive toxicity data to support continued development of DM199 (rinvecalinase alfa) for the treatment of preeclampsia (PE). DiaMedica believes, based on the FDA’s feedback, that the previously completed rat reproductive toxi...

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held in New York on June 2-4 2026. Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 3:45 PM ET Format: Corporate Presentation If you are interested in...
Back to Newsroom